{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:36:35Z","timestamp":1790796995033,"version":"4.1.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Measurable residual disease (MRD) status in chronic lymphocytic leukemia (CLL), assessed on and after treatment, correlates with increased progression-free and overall survival benefit. More recently, MRD assessment has been included in large clinical trials as a primary outcome and is increasingly used in routine practice as a prognostic tool, a therapeutic goal, and potentially a trigger for early intervention. Modern therapy for CLL delivers prolonged remissions, causing readout of traditional trial outcomes such as progression-free and overall survival to be inherently delayed. This represents a barrier for the rapid incorporation of novel drugs to the overall therapeutic armamentarium. MRD offers a dynamic and robust platform for the assessment of treatment efficacy in CLL, complementing traditional outcome measures and accelerating access to novel drugs. Here, we provide a comprehensive review of recent major clinical trials of CLL therapy, focusing on small-molecule inhibitors and monoclonal antibody combinations that have recently emerged as the standard frontline and relapse treatment options. We explore the assessment and reporting of MRD (including novel techniques) and the challenges of standardization and provide a comprehensive review of the relevance and adequacy of MRD as a clinical trial endpoint. We further discuss the impact that MRD data have on clinical decision-making and how it can influence a patient\u2019s experience. Finally, we evaluate how upcoming trial design and clinical practice are evolving in the face of MRD-driven outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2023.1130617","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T08:50:56Z","timestamp":1677055856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials"],"prefix":"10.3389","volume":"13","author":[{"given":"A.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Goradia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Martinez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PEM.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after fcr chemoimmunotherapy in previously untreated patients with cll: Updated results of the Cll8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (Cll10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with cll and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18075","article-title":"Guideline for the treatment of chronic lymphocytic leukaemia","volume":"197","author":"Walewska","year":"2022","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: Esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"B6","unstructured":"Wierda WBJ\n            AbramsonJ\n            AwanF\n            BilgramiS\n            BociekG\n          Nccn guidelines version 1.2023 chronic lymphocytic Leukemia\/Small lymphocytic lymphoma2022"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01009-z","article-title":"Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia","volume":"35","author":"Letestu","year":"2021","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in Relapsed\/Refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the murano phase iii study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.140","article-title":"Standardized mrd flow and aso igh rq-pcr for mrd quantification in cll patients after rituximab-containing immunochemotherapy: A comparative analysis","volume":"23","author":"B\u00f6ttcher","year":"2009","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (Cll) who achieve partial response: Comprehensive analysis of two phase iii studies of the German cll study group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using mrd as a surrogate end point in cll","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in ighv-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in cll after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in cll","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized gcllsg Cll8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: Primary analysis results from the minimal residual disease cohort of the randomized phase ii captivate study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"Iwcll guidelines for diagnosis, indications for treatment, response assessment, and supportive management of cll","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B18","unstructured":"Summary of opinion (Post authorisation) - brukinsa2022"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-453092","article-title":"How will b-Cell-Receptor-Targeted therapies change future cll therapy","volume":"123","author":"Jones","year":"2014","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (Ga101), a novel type ii anti-Cd20 monoclonal antibody, for the treatment of patients with b-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1182\/blood.V124.21.3307.3307","article-title":"Minimal residual disease (Mrd) by 8-color flow cytometry (Flow-mrd) and igh clonospecific quantitative pcr (Aso rqpcr) reached similar performances for evaluation of cll treatment in a phase ii clinical trial: Cross validation of the methods","volume":"124","author":"Letestu R","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European research initiative in cll (Eric) update on the international harmonised approach for flow cytometric residual disease monitoring in cll","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: An European research initiative on cll study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmw006","article-title":"Optimization and validation of an 8-color single-tube assay for the sensitive detection of minimal residual disease in b-cell chronic lymphocytic leukemia detected Via flow cytometry","volume":"47","author":"Dowling","year":"2016","journal-title":"Lab Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/cyto.b.21067","article-title":"A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia","volume":"84","author":"Sartor","year":"2013","journal-title":"Cytomet B Clin Cytom"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21953","article-title":"14-color single tube for flow cytometric characterization of Cd5+ b-lpds and high sensitivity automated minimal residual disease quantitation of Cll\/Sll","volume":"100","author":"Goshaw","year":"2021","journal-title":"Cytomet B Clin Cytom"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1919658","article-title":"A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia","volume":"62","author":"Bazinet","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120","article-title":"Euroflow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.3390\/ijms20112832","article-title":"Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies","volume":"20","author":"Sanchez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1118357109","article-title":"High-throughput vdj sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12887","article-title":"Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. a comparative analysis of flow cytometry and aso igh rq-pcr","volume":"166","author":"Raponi","year":"2014","journal-title":"Br J Haematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"519\u201328","DOI":"10.1182\/blood.2022017411","article-title":"Detecting measurable residual disease beyond 10-4 through an ighv leader-based ngs approach improves prognostic stratification in cll","volume":"141","author":"Hengeveld","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative pcr: Principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in Relapsed\/Refractory chronic lymphocytic leukemia: The clarity study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (Elevate tn): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (Cll14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of cll: Primary analysis of the captivate fd cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater Arnon","year":"2022","journal-title":"NEJM Evidence"},{"key":"B43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13063-020-04971-2","article-title":"A platform trial in practice: Adding a new experimental research arm to the ongoing confirmatory flair trial in chronic lymphocytic leukaemia","volume":"22","author":"Howard","year":"2021","journal-title":"Trials"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2021-146161","article-title":"A randomised phase iii study of venetoclax-based time-limited combination treatments (Rve, gve, give) vs standard chemoimmunotherpay (Cit: Fcr\/Br) in frontline chronic lymphocytic leukaemia (Cll) of fit patients: First Co-primary endpoint analysis of the international intergroup gaia (Cll13) trial","volume":"138","author":"Eichhorst B","year":"2021","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18427","article-title":"Obinutuzumab as consolidation after chemo-immunotherapy: Results of the uk national cancer research institute phase Ii\/Iii galactic trial","volume":"199","author":"Munir","year":"2022","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable mrd and updated outcomes in Relapsed\/Refractory cll after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"crossref","first-page":":222\u20133","DOI":"10.1182\/blood-2022-166700","article-title":"Mrd4 eradication at 6 months and early clearance of mrd with combination of ibrutinib plus venetoclax results in sustained clinical and mrd responses: Exploratory analysis of the blood cancer uk tap clarity study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (Helios): A randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"crossref","first-page":"228\u201330","DOI":"10.1182\/blood-2022-156070","article-title":"Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): The glow study","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"crossref","first-page":":231\u20133","DOI":"10.1182\/blood-2022-170463","article-title":"Combination of ibrutinib plus venetoclax with mrd-driven duration of treatment results in a higher rate of mrd negativity in ighv unmutated than mutated cll: Updated interim analysis of flair study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2021-148666","article-title":"First prospective data on minimal residual disease (Mrd) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of cll in elderly or unfit patients: The glow study","volume":"138","author":"Munir","year":"2021","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1074\/mcp.RA117.000425","article-title":"Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia","volume":"17","author":"Mayer","year":"2018","journal-title":"Mol Cell Proteomics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting btk with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13063-017-2138-6","article-title":"Assessment of ibrutinib plus rituximab in front-line cll (Flair trial): Study protocol for a phase iii randomised controlled trial","volume":"18","author":"Collett","year":"2017","journal-title":"Trials"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the elevate-tn study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to fcr in previously untreated cll: Results of the phase iii ncri flair trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"crossref","first-page":":46\u20137","DOI":"10.1097\/01.HS9.0000843472.57904.29","article-title":"The combination of ibrutinib plus venetoclax results in a high rate of mrd negativity in previously untreated cll: The results of the planned interim analysis of the phase 3 ncri flair trial","volume":"6","author":"Hillmen","year":"2022","journal-title":"HemaSphere"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12825","article-title":"Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I\/Ii multicentre trial","volume":"98","author":"Al-Sawaf","year":"2017","journal-title":"Eur J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Final analysis of calgb 10101","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14342","article-title":"Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from ncrn Cll207: A phase ii trial assessing alemtuzumab consolidation","volume":"176","author":"Varghese","year":"2017","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (Cll) in first remission\u2013experience on safety and efficacy within a randomized multicenter phase iii trial of the German cll study group (Gcllsg)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/diagnostics12061305","article-title":"Digital droplet pcr in hematologic malignancies: A new useful molecular tool","volume":"12","author":"Galimberti","year":"2022","journal-title":"Diagnostics"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16442","article-title":"Droplet digital pcr is a sensitive tool for the detection of Tp53 deletions and point mutations in chronic lymphocytic leukaemia","volume":"189","author":"Frazzi","year":"2020","journal-title":"Br J Haematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13246","article-title":"Droplet digital pcr analysis of Notch1 gene mutations in chronic lymphocytic leukemia","volume":"7","author":"Minervini","year":"2016","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.579762","article-title":"Multiplexed droplet digital pcr assays for the simultaneous screening of major genetic alterations in tumors of the central nervous system","volume":"10","author":"Appay","year":"2020","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bjh.17623","article-title":"Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: Mass spectrometry versus next-generation sequencing","volume":"196","author":"Shanmuganathan","year":"2022","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00415","article-title":"Validation of cytof against flow cytometry for immunological studies and monitoring of human cancer clinical trials","volume":"9","author":"Gadalla","year":"2019","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"748","DOI":"10.12688\/f1000research.11622.3","article-title":"Cytof workflow: Differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.3390\/cancers14102537","article-title":"Artificial intelligence enhances diagnostic flow cytometry workflow in the detection of minimal residual disease of chronic lymphocytic leukemia","volume":"14","author":"Salama","year":"2022","journal-title":"Cancers"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.12.101","article-title":"Unsupervised computational detection of measurable residual disease in chronic lymphocytic leukaemia","volume":"54","author":"Nguyen P","year":"2022","journal-title":"Pathology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase ii trial of the German chronic lymphocytic leukemia study group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in cll","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0132-y","article-title":"Serial minimal residual disease (Mrd) monitoring during first-line fcr treatment for cll may direct individualized therapeutic strategies","volume":"32","author":"Thompson","year":"2018","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from resonate-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"B80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 resonate study in patients with previously treated Cll\/Sll","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (Resonate-17): A phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-469627","article-title":"Tp53, Sf3b1, and Notch1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: Six-year follow-up of the gcllsg Cll3x trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1130617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T08:51:02Z","timestamp":1677055862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1130617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":82,"alternative-id":["10.3389\/fonc.2023.1130617"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1130617","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"article-number":"1130617"}}